NeurAxis Q3 2026 net loss more than triples year over year to $6.55 million
NRXS•NeurAxis’ third-quarter 2026 net loss more than tripled to $6.55 million, including $4.3 million in one-time stock compensation charges. Revenue more than doubled to $2.03 million, and the company reported $4.5 million in cash at September 30.
1. Quarterly results
NeurAxis’ third-quarter 2026 net loss more than tripled year over year to $6.55 million, reflecting $4.3 million in one-time stock compensation charges. Revenue more than doubled to $2.03 million as expanded insurance coverage increased IB-Stim utilization.
2. Cash and clearance
Cash totaled $4.5 million at September 30, and NeurAxis raised an additional $1.7 million through its at-the-market facility in the fourth quarter. IB-Stim received FDA clearance for functional dyspepsia-related abdominal pain with associated nausea in patients ages 8 and older.
